rutgers-university
(2)Aahuti Patel and the quiet arithmetic behind a $94 billion company
Aahuti Patel works where forecasts become choices: inside the North American finance operation of Johnson & Johnson. Her sparse public profile reveals a career built around scale, judgment and the unglamorous discipline of making numbers useful.
Dinesh V. Patel
Dinesh V. Patel, Ph.D. is the President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), a Newark, California-based biopharmaceutical company he has led since December 2008. With over 38 years spanning medicinal chemistry, drug discovery, venture capital co-founding, and three CEO stints, Patel has guided Protagonist from a peptide-platform startup to a company with its first FDA-approved drug - ICOTYDE (icotrokinra), approved March 2026 as the world's first targeted oral peptide for moderate-to-severe plaque psoriasis, partnered with Johnson & Johnson.